Status update on VB C-02 clinical trial with VB10.16 and immune checkpoint inhibitor atezolizumab in patients with advanced cervical cancer

- VB C-02 clinical trial with the therapeutic cancer vaccine VB10.16 and immune checkpoint inhibitor atezolizumab (Tecentriq®) is on track to finalize enrollment during fourth quarter 2021

- Per protocol interim safety analysis has been conducted as planned with no safety concerns and a recommendation to continue the trial as planned

Oslo, Norway, April 30, 2021 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced that the Safety Review Committee meeting to evaluate the per protocol Interim Safety Analysis for the VB C-02 trial concluded to continue the recruitment as planned.

Investigational sites in 6 European countries are now screening and enrolling patients in the VB C-02 clinical trial. The trial is expected to end the enrolment period in fourth quarter 2021 and plans to report interim clinical data around year-end.

The VB C-02 clinical trial is a multi-centre, open-label clinical trial testing VB10.16, a targeted cancer vaccine, and immune checkpoint inhibitor atezolizumab in patients with advanced HPV16 positive cervical cancer and will enroll up to 50 patients. The clinical trial has the ClinicalTrials.gov Identifier: NCT04405349.

About Vaccibody

Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies. The Company develops vaccines for the treatment cancer and infectious diseases. Vaccibody's vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen-specific immune responses and elicit efficacious clinical responses. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment of melanoma, lung- , head and neck, renal-, and bladder cancer; and VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer and

cancer of the head & neck. Further, the Company has collaborations with Roche and Nektar Therapeutics within oncology.

Additionally, Vaccibody intends to leverage the potential of its platform in infectious disease indications, including its second-generation COVID-19 vaccine program, VB10.COV2.

Vaccibody's shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC. Further information about Vaccibody may be found at http://www.vaccibody.com

Contact for Vaccibody:

CEO Michael Engsig
Vaccibody AS
Cell: +45 6173 1509
mengsig@vaccibody.com

Vaccibody AS
Oslo Research Park
Gaustadalléen 21
0349 Oslo, Norway

Forward-looking statements for Vaccibody

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.